在慢性淋巴细胞白血病中,IL-25对恶性B细胞存活和T细胞激活的影响
Mehrnoosh Pashei1, Farahnaz Ghahremanfard2, Ehsan Manouchehri Doulabi3
1Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. meh.pashaei@yahoo.com.
Iranian journal of allergy, asthma, and immunology
|July 31, 2023
概括
干白素-25 (IL-25) 通过刺激T细胞和减少瘤细胞死亡,促进慢性淋巴细胞白血病 (CLL) 细胞生存. 这表明IL-25通过IL-17RB等与炎症相关的受体在CLL发育中发挥作用.
科学领域:
- 免疫学 免疫学 免疫学
- 血液学 血液学 血液学
- 细胞生物学 细胞生物学
背景情况:
- 慢性淋巴细胞白血病 (CLL) 涉及T细胞失调和转向T助手2反应,支持白血病B细胞存活.
- 干白素-25 (IL-25) 参与启动T助手2细胞反应,其受体IL-17RB对IL-25信号转导至关重要.
- 瘤微环境中IL-25的存在可能会影响周围瘤细胞的T细胞介导支持.
研究的目的:
- 为了研究介质素-25 (IL-25) 在慢性淋巴细胞白血病 (CLL) 的生物机制中的作用.
- 评估来自CLL患者和健康个体的T细胞和B细胞中IL-17RB的表达.
- 为了评估IL-25对T细胞激活和B细胞活力和CLL细胞亡的影响.
主要方法:
- 实时聚合酶连锁反应和流细胞测量被用来测量IL-17RB表达在外周血液单核细胞 (PBMCs) 从九个CLL患者和九个健康对照.
- 使用磁激活细胞分类 (MACS) 净化白血病B细胞.
- 用复合人体IL-25培养了PBMC和纯化的白血病B细胞,随后进行了MTT测定和AnnexinV/7AAD染色,以评估细胞活力和亡. 还测量了T淋巴细胞上的CD69表达和T和B细胞上的IL-17RB.
主要成果:
- 与健康个体相比,CLL患者的基础IL-17RB表达显著更高.
- 用IL-25培养增加了IL-17RB+ T细胞 (CD3+),IL-17RB+ B细胞 (CD19+) 和激活的T细胞 (CD69+) 的百分比,在CLL患者中比健康受试者更多.
- IL-25治疗降低了CLL细胞的亡率,并刺激了T细胞,表明瘤细胞的存活率提高.
结论:
- IL-25可能通过上调IL-17RB等与炎症相关的受体来促进CLL瘤细胞的存活.
- 在CLL患者中,IL-25似乎刺激T细胞并抑制B细胞死亡.
- 这些发现表明IL-25在慢性淋巴细胞白血病的发病和发展中可能发挥作用.
相关概念视频
T Cell Types and Functions
1.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.1K
B Cell Activation and Differentiation
1.8K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.8K


